TOMY International, Inc. manufactures, markets, and sells a range of toys and nursery products. The company is a wholly owned subsidiary of Japan-based TOMY Company, Ltd. The company was incorporated in 1987 and is based in Oak Brook, Illinois with locations in Dyersville, Iowa; and Canton, Massachusetts. It has international offices in Australia, Germany, the United Kingdom, France, the Benelux, Spain, China, and Hong Kong, and reaches its target consumers through multiple channels of distribution supporting more than 25,000 retail outlets.
TOMY International is a leading global designer, producer and marketer of a broad range of innovative, high-quality toys sold to preschoolers, youths and adults under the TOMY® and Ertl® brands as well as products for parents, infants and toddlers marketed under the The First Years®, JJ Cole® Collections and Boon® brands. TOMY International also markets its products under popular licensed properties such as John Deere, Pokémon, Sonic the Hedgehog, Lamaze, Disney Baby properties including Mickey and Minnie Mouse, Princesses, Cars, Fairies and Toy Story, and other well-known licenses. TOMY International’s mission is to make the world smile.
You can purchase their products from link below.
Top Ads Today
- Honda R&D Innovations, Inc. - Honda’s global information technology research and development (17 views)
- NHK Spring (Thailand) Co., Ltd. - World's Largest Independent Spring Manufacturer (14 views)
- Daiichi Sankyo, Inc. - Pharmaceutical treatment of hypertension, dyslipidemia and others (12 views)
- NTT DOCOMO USA, Inc. - US subsidiary of NTT DOCOMO, Japan’s largest telecommunications company (6 views)
- Honda Aero, Inc. (HAI) - Developing a variety of aircraft engines (4 views)
- Power Japan Plus (US Office) - New Ryden Dual Carbon Battery (4 views)
- PanaHome Malaysia Sdn Bhd - A Home-Building Company in Malaysia (4 views)
- Handcrafted premium Japanese kitchen knives - Yoshihiro Cutlery (4 views)
- Japan Society of Boston (3 views)
- Taiho Ventures, LLC - Venture Capital for investing early-stage preclinical oncology companies (3 views)